Akeso

Akeso, Inc. develops a diversified antibody portfolio targeting solid and hematologic cancers (PD‑1/CTLA‑4, PD‑1/VEGF, CD47) and chronic inflammatory disease (IL‑12/IL‑23, IL‑17). A global pipeline in oncology and immunology with strong growth prospects.

Headquarters: China (CHN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 3,529
HQ: Zhongshan

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
9926	Akeso Cap: 107.3B	EQUITY	HKG	HKD	KYG0146B1032	Active	📈